Surgical adhesives developer OptMed (OMED) has filed to carry a $23M preliminary public providing.
The medical gadget firm didn’t disclose the scale and pricing of the deal in its S-1 filing, however indicated in its filing fee schedule that it was in search of round $23M, a quantity that’s more likely to change.
The corporate hopes to record its shares on Nasdaq underneath the image OMED. EF Hutton is serving as lead bookrunner.
OptMed has developed two surgical adhesives, BondEase and TearEase. The corporate acquired FDA clearance for BondEase in 2015 however must refile the applying as a consequence of modifications made to the product and its manufacturing course of. OptMed stated it plans to file for FDA clearance for each merchandise inside three months of the IPO.
The corporate remains to be working within the purple. For 2021, OptMed reported a web lack of $4.4M with no income.
For extra IPO information, take a look at SA’s IPO News page.